Odessa American

ViaCyte Announces Initiation of Phase 2 Study of Encapsulated Cell Therapy for Type 1 Diabetes Patients

SAN DIEGO, Feb. 3, 2021 /PRNewswire/ — ViaCyte, Inc., a clinical-stage regenerative medicine company, today announced that the first type 1 diabetes (T1D) patients have been implanted in a Phase 2 ...
Business Insider

ViaCyte and W. L. Gore & Associates Announce Collaborative Research Agreement to Develop Novel Implantable Delivery Technologies for Cell Therapies

SAN DIEGO and NEWARK, Del., March 29, 2017 /PRNewswire/ -- ViaCyte, Inc., a privately-held regenerative medicine company, and W. L. Gore & Associates, Inc. ("Gore"), a global materials science company ...
BioWorld

VC-01 Diabetes Therapy 'Cells' Investors on Viacyte

Tiny Viacyte Inc. is going after a whopper of an indication with a stem cell-derived cell therapy to treat Type I and insulin-dependent Type II diabetes. The novelty of its combination product, known ...
GEN

ViaCyte’s Sweet Three-Pronged Attack against Type 1 Diabetes

A century after researchers from the University of Toronto discovered the hormone as a treatment for diabetes in humans, insulin—and recombinant DNA versions brought to market in the past four decades ...
GEN

Vertex to Acquire ViaCyte for $320M, Growing Diabetes Cell Therapy Pipeline

Vertex Pharmaceuticals said today it has agreed to acquire ViaCyte for $320 million cash, in a deal that bolsters the buyer’s diabetes pipeline with ViaCyte’s triple-pronged attack against the disease ...
Nasdaq

CRISPR Therapeutics and ViaCyte, Inc. to Start Clinical Trial of the First Gene-Edited Cell Replacement Therapy for Treatment of Type 1 Diabetes

ZUG, Switzerland and CAMBRIDGE, Mass. and SAN DIEGO, Nov. 16, 2021 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (NASDAQ: CRSP), a biopharmaceutical company focused on developing transformative gene-based ...